Seranova Bio is striving to establish a new paradigm for therapeutic target discovery. Our REAP platform combines high-quality, comprehensive protein sampling with next-generation DNA sequencing to profile patients’ autoantibodies with higher throughput and fidelity than existing technologies. Our technological breakthrough reveals, in much greater depth, the underlying humoral response to disease and provides critical insights to drug developers. Seranova Bio aims to collaborate with pharmaceutical partners to discover novel therapeutic targets and develop new treatments to autoimmune disease, neurodegeneration, and cancer.